Evidence map›Paper›PMID 30448897›Full record

Observational studyBreast cancer research and treatment2019

Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.

Brian L Sprague, Pamela M Vacek, Sally D Herschorn, Ted A James, Berta M Geller, Amy Trentham-Dietz, Janet L Stein, Donald L Weaver

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Collagen Organization in Relation to Ductal CarcinomaCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  5. HER2-Overexpressing Ductal CarcinomaCancer prevention research (Philadelphia, Pa.) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brian L SpragueDepartment of Surgery, University of Vermont, 1 S. Prospect St, UHC Room 4425, Burlington, VT, 05401, USA. brian.sprague@uvm.edu.ORCID http://orcid.org/0000-0001-7948-8317
Pamela M VacekUniversity of Vermont Cancer Center, University of Vermont, Burlington, VT, USA.
Sally D HerschornDepartment of Radiology, University of Vermont, Burlington, VT, USA.
Ted A JamesDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Berta M GellerDepartment of Family Medicine, University of Vermont, Burlington, VT, USA.
Amy Trentham-DietzDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Janet L SteinUniversity of Vermont Cancer Center, University of Vermont, Burlington, VT, USA.
Donald L WeaverUniversity of Vermont Cancer Center, University of Vermont, Burlington, VT, USA.

Funding

Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Vermont Screening Process Documentation UnitU54CA163303 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L · 2011 to 2017
$6.4M
Vermont Breast Cancer Molecular Characterization LaboratoryU01CA196383 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L, STEIN, JANET L · 2015 to 2020
$5.4M
National Cancer Institute P01 CA154292National Cancer Institute U01 CA196383National Cancer Institute U54 CA163303NCI NIH HHS P01 CA154292NCI NIH HHS U01 CA196383NCI NIH HHS U54 CA163303Patient-Centered Outcomes Research Institute PCS-1504-30370University of Vermont Cancer Center 032800
6 · The paper itself

Abstract

purposeLong-term disease-free survival patterns following surgical, radiation, and endocrine therapy treatments for ductal carcinoma in situ (DCIS) are not well characterized in general US practice.

methodsWe identified 1252 women diagnosed with DCIS in Vermont during 1994-2012 using data from the Vermont Breast Cancer Surveillance System, a statewide registry of breast imaging and pathology records. Poisson regression and Cox regression with time-varying hazards were used to evaluate disease-free survival among self-selected treatment groups.

resultsWith 7.8 years median follow-up, 192 cases experienced a second breast cancer diagnosis. For women treated with breast-conserving surgery (BCS) alone, the annual rate of second events decreased from 3.1% (95% CI 2.2-4.2%) during follow-up years 1-5 to 1.7% (95% CI 0.7-3.5%) after 10 years. In contrast, the annual rate of second events among women treated with BCS plus adjuvant radiation therapy increased from 1.8% (95% CI 1.1-2.6%) during years 1-5 to 2.8% (95% CI 1.6-4.7%) after 10 years (P < 0.05 for difference in trend compared to BCS alone). Annual rates of second events also increased over time among women treated with BCS plus adjuvant radiation and endocrine therapy (P = 0.01 for difference in trend compared to BCS alone). The rate of contralateral events increased after 10 years for all groups with adjuvant treatments. The rate of second events did not vary over time among women who underwent ipsilateral mastectomy (P = 0.62).

conclusionsLong-term risk of a second event after DCIS varies over time in a manner dependent on initial treatment.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleHumansMastectomyMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalRadiotherapyRisk FactorsTime FactorsVermontAntineoplastic Agents, HormonalBreast cancerCohort studiesDisease-free survivalDuctal carcinoma in situTreatment outcome

Identifiers

PMID30448897
PMCPMC6420371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.